⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20919462 | 1.00 | HSD17B10 (0.45) | — | |
| SCHEMBL29958227 | 1.00 | HSD17B10 (0.45) | — | |
| Bromide SCHEMBL29963987 | 0.97 | HSD17B10 (0.43) | — | |
| SCHEMBL441180 | 0.97 | — | — | |
| SCHEMBL1283759 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL3021853 | 0.94 | — | — | |
| SCHEMBL740177 | 0.91 | — | — | |
| SCHEMBL28374092 | 0.84 | — | — | |
| SCHEMBL5501959 | 0.81 | HSD17B10 (0.36) | — | |
| Cadaverine Tartrate SCHEMBL15738659 | 0.81 | HSD17B10 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867549-A | 1H-pyrrolo [3,2-c ] pyridine and 1H-pyrrolo [2,3-c ] pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | 百时美施贵宝公司 | 2023-03-28 | — | — | CN | claimed |
| US-11530181-B2 | IL-6 inhibitors and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-12-20 | — | — | US | claimed |
| WO-2022152274-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | 深圳康溯医药科技有限公司 | 2022-07-21 | — | — | WO | claimed |
| WO-2016046782-A1 | IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-03-31 | — | — | WO | claimed |
| EP-2968145-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | Mallinckrodt LLC (US) | 2016-01-20 | — | — | EP | claimed |
| EP-2864309-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | Cadila Healthcare Limited (IN) | 2015-04-29 | — | — | EP | claimed |
| WO-2014160392-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-09-18 | — | — | US | claimed |
| WO-2014002105-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2014-01-03 | — | — | WO | claimed |
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | claimed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | claimed |
| US-6514977-B1 | For treating p38 kinase mediated disorders | G.D. SEARLE & COMPANY | 2003-02-04 | — | — | US | claimed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | claimed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | claimed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | claimed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | claimed |
| CN-1342157-A | Substituted pyrazoles ASP38 kinase inhibitors | SEARLE & CO (US) | 2002-03-27 | — | — | CN | claimed |
| EP-1144403-A1 | SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000031063-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | claimed |